Pfizer To Cut Costs After Lowering Its Revenue Projection Due To Lower COVID-19 Vaccine Sales
Lower-than-expected revenues from sale of its COVID-19 vaccine and treatment, Pfizer has been forced to lower revenue estimates for the full year by 13% and announce that it would cut $3.5 billion in employees and expenses. Following the development of the vaccine Comirnaty with German partner BioNTech SE and the antiviral medication Paxlovid independently, Pfizer generated record revenue in…









